Lian Yu
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study.
Journal: Translational lung cancer research
Published: February 09, 2023
Multi-target angiogenesis inhibitor combined with PD-1 inhibitors may benefit advanced non-small cell lung cancer patients in late line after failure of EGFR-TKI therapy.
Journal: International journal of cancer
Published: February 07, 2023
Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer.
Journal: Cancer medicine
Published: July 28, 2022
Pathological Stage N1 Limited-Stage Small-Cell Lung Cancer Patients Can Benefit From Surgical Resection.
Journal: Clinical lung cancer
Published: November 16, 2021
FAM207BP, a pseudogene-derived lncRNA, facilitates proliferation, migration and invasion of lung adenocarcinoma cells and acts as an immune-related prognostic factor.
Journal: Life sciences
Published: September 11, 2020
Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
Journal: International immunopharmacology
Published: June 16, 2020
Selection of cross-protective antigens from outer membrane proteins of three pathogenic vibrios isolated from infected large yellow croaker (Pseudosciaena crocea)
Journal: Sheng wu gong cheng xue bao = Chinese journal of biotechnology
Published: April 19, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026